Taken together, our pharmaceutical data suggest that it is feasible to develop a kisspeptin medical product for nasal delivery (in solution or powder) that is easily self-administered by patients at home, similar to the well-established clinically used intranasal desmopressin for diabetes insipidus (arginine vasopressin deficiency). The gene discussed is KISS1; the disease is neurohypophyseal diabetes insipidus.